03 Oct 2026, 15:02 IST
Gland Pharma Limited
Motilal Oswal (MOFSL) · Buy
The report expects Gland to outperform in the US market with 23% YoY growth supported by Flovent HFA exclusivity, and forecasts 42% YoY EBITDA growth.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.